NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=107033&from=3 CLASS PERIO ...

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics, Inc. (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024. Verve is a "clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines." For more information, ...

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"), of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If you purchased Verve Therapeutics securities during the Class Period you may be entitled to compensation without payment of an ...

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=106360&from=3 CLASS PERIO ...

NEW YORK, Sept. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=105571&from=4 CLASS PERIOD: ...

NEW YORK, Sept. 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"), of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If you purchased Verve Therapeutics securities during the Class Period you may be entitled to compensation without payment of a ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Verve between August 9, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983- 9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIR ...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Verve Therapeutics, Inc. ("Verve Therapeutics" or the "Company") (NASDAQ: VERV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Verve Therapeutics investors who were adversely affected by alleged securities fraud between August 9, 2022 and April 1, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1 ...

NEW YORK, Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=104021&from=4 CLASS PERIOD: ...

文章核心观点 - 公司Verve Therapeutics被指在2022年8月9日至2024年4月1日期间做出了虚假或误导性陈述,隐瞒了VERVE-101临床试验可能被中止的情况,并夸大了其专有脂质纳米颗粒(LNP)递送系统的潜在利益[4] - 这些行为导致投资者遭受损失,Rosen律师事务所代表投资者提起集体诉讼,要求投资者在2024年10月28日之前加入集体诉讼[1][2] 关于集体诉讼 - Rosen律师事务所是一家专注于证券集体诉讼的全球性投资者权益律师事务所,在此类诉讼中有丰富的经验和成功案例[3] - 投资者可以通过Rosen律师事务所的网站或致电律师加入集体诉讼,不需要支付任何费用[2] - 在集体诉讼中,投资者可以选择担任首席原告,代表其他集体成员参与诉讼[2] 关于Verve Therapeutics - Verve Therapeutics是一家生物技术公司,正在研发一种名为VERVE-101的基因编辑药物,旨在永久性地关闭肝脏中的PCSK9基因,从而降低低密度脂蛋白胆固醇(LDL-C)[4] - 公司在临床试验过程中可能隐瞒了VERVE-101试验可能被中止的情况,并夸大了其LNP递送系统的优势[4]